NCT00491387

Sympathetic Nervous System Modulation in Hypertension

Sympathetic Nervous System Modulation in Hypertension by Beta-adrenergic Blockade

• Status: Terminated
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 24 (actual)
• Sponsor: University of Cincinnati · Academic / Other
• Sex: All
• Age: 20 Years – 80 Years
• Healthy volunteers: Not accepted

Summary

This is a study of patients with high blood pressure who are already treated with an angiotensin converting enzyme inhibitor or receptor blocker and have achieved good or fair blood pressure control. The hypothesis is that addition of the beta-adrenergic receptor blocker, sustained-release metoprolol, will provide additional blockade of the sympathetic nervous system, thereby further improving left ventricular filling and blood pressure control.

Detailed description

Patients were to receive sympathetic cardiac innervation testing with I-123 MIBG at baseline and again after receiving a titrate dose of beta-blocker. Data were to be assesses by repeated measures testing.

Conditions

• Hypertension

Interventions

Type	Name	Description
DRUG	Metoprolol Succinate	Once daily, oral, 12.5 mg to 200 mg, dose titrated to reduce heart rate by 20% or to less than 65 beats per minute.

Timeline

• Start date: 2007-08-01
• Primary completion: 2009-01-01
• Completion: 2009-01-01
• First posted: 2007-06-26
• Last updated: 2018-02-07
• Results posted: 2011-04-19